Bryan D. Anderson

Nanoparticle conversion chemistry: Kirkendall effect, galvanic exchange, and anion exchange

Bryan D. Anderson, Joseph B. Tracy · Nanoscale · 2014 · 351 citations

Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-β Type I Receptor Kinase Domain

J. Scott Sawyer, Bryan D. Anderson, Douglas W. Beight et al. · Journal of Medicinal Chemistry · 2003 · 237 citations · Full text

Drug Target, Pyrazole-based Inhibitors, Pharmaceutical Chemistry +20

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Jonathan M. Yingling, William T. McMillen, Lei Yan et al. · Oncotarget · 2017 · 168 citations · Full text

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain

J. Scott Sawyer, Douglas W. Beight, Karen S. Britt et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 161 citations

Molecular Pharmacology, Medicinal Chemistry, Pharmaceutical Chemistry +9

Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity

Robert M. Campbell, Bryan D. Anderson, Nathan A. Brooks et al. · Molecular Cancer Therapeutics · 2013 · 115 citations

Drug Target, Antitumor Activity, P38 Mapk +20